BioNTech SE reported €2.87B of revenue over the trailing twelve months, +4.3% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €2.87B (to FY2025). Net Income: −€1.14B, trailing twelve months to FY2025. Free Cash Flow: €281M, trailing twelve months to FY2025. Op Margin: −49%, trailing twelve months to FY2025.

BNTXBioNTech SE

HealthcareUSD

$98.72

$83.8952 weeks$119.34

BNTX as reported

BioNTech SE reported €2.87B of revenue over the trailing twelve months, +4.3% on the year before. 10 reported series are charted on this page, each one as filed.

€2.87B

Revenue, trailing twelve months · to FY2025 · +4.3% against the twelve months before

Net Income: −€1.14B
Net Income · +71% year on year · trailing twelve months to FY2025
Free Cash Flow: €281M
Free Cash Flow · −456% year on year · trailing twelve months to FY2025
Op Margin: −49%
Op Margin · trailing twelve months to FY2025

Every series Ryufin has for BNTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€2.87B	+4.3%	FY2025
Net Income	−€1.14B	+71%	FY2025
EPS	−€4.70	+70%	FY2025
Gross Margin	78%	n/a	FY2025
Op Margin	−49%	n/a	FY2025
Net Margin	−40%	n/a	FY2025
ROE	−5.9%	n/a	FY2025
ROA	−5.2%	n/a	FY2025
ROIC	119%	n/a	FY2021
Free Cash Flow	€281M	−456%	FY2025